FIRST TRIMESTER SERUM ANGIOGENIC AND ANTI-ANGIOGENIC FACTORS IN WOMEN WITH CHRONIC HYPERTENSION FOR THE PREDICTION OF PREECLAMPSIA.
An imbalance between angiogenic and antiangiogenic factors is thought to be a central pathogenetic mechanism in preeclampsia. In pregnancies that subsequently develop preeclampsia the maternal serum concentration of the angiogenic placental growth factor (PLGF) is decreased from as early as the first trimester of pregnancy and the concentration of the antiangiogenic soluble fms-like tyrosine kinase-1 (sFLT-1) is increased in the last few weeks before the clinical presentation of the disease. Chronic hypertension, which complicates 1-2% of pregnancies, is the highest risk factor for development of preeclampsia among all other factors in maternal demographic characteristics and medical history. Two previous studies in women with chronic hypertension reported that first-trimester serum PLGF and sFLT-1 were not significantly different between those that developed superimposed preeclampsia and those that did not, whereas a third study reported that concentrations of PLGF were decreased. To investigate whether in women with chronic hypertension serum concentrations of PLGF and sFLT-1 and sFLT-1/PLGF ratio at 11+0 to 13+6 weeks' gestation are different between those that developed superimposed preeclampsia and those that did not and to compare these values to those in normotensive controls. The study population comprised of 650 women with chronic hypertension, including 202 that developed superimposed preeclampsia and 448 that did not develop preeclampsia, and 142 normotensive controls. Maternal serum concentration of PLGF and sFLT-1 were measured by an automated biochemical analyzer and converted into multiples of the expected median (MoM) using multivariate regression analysis in the control group. Comparisons of PLGF, sFLT-1 and sFLT-1/PLGF ratio in MoM values between the two groups of chronic hypertension and the controls were made by the ANOVA or the Kruskal-Wallis test. In the group of chronic hypertension that developed preeclampsia, compared to those that did not develop preeclampsia, there were significantly lower median concentrations of serum PLGF MoM (0.904, interquartile range (IQR) 0.771-1.052 vs. 0.948, IQR 0.814-1.093; p=0.014) and sFLT-1 MoM (0.895, IQR 0.760-1.033 vs 0.938, IQR 0.807-1.095; p=0.013) and they were both lower than in the normotensive controls (1.009, IQR 0.901-1.111 and 0.991, IQR 0.861-1.159, respectively; P<0.01 for both). There were no significant differences between the three groups in sFLT-1 / PLGF ratio. In women with chronic hypertension serum PLGF and sFLT-1 provided poor prediction of superimposed preeclampsia (area under the curve 0.567, 95% confidence interval (CI) 0.537-0.615 and 0.546, 95% CI 0.507-0.585, respectively). Women with chronic hypertension, and particularly those who subsequently developed preeclampsia, have reduced first trimester concentrations of both PLGF and sFLT-1.